Schwab Charles Investment Management Inc. increased its position in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 1.8% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 115,218 shares of the medical research company’s stock after acquiring an additional 2,070 shares during the period. Schwab Charles Investment Management Inc. owned approximately 0.39% of Bio-Rad Laboratories worth $26,075,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently modified their holdings of BIO. BlackRock Inc. raised its stake in Bio-Rad Laboratories by 9,953.4% in the 1st quarter. BlackRock Inc. now owns 1,733,111 shares of the medical research company’s stock worth $345,478,000 after acquiring an additional 1,715,872 shares during the last quarter. BlueCrest Capital Management Ltd raised its stake in shares of Bio-Rad Laboratories by 183.5% during the 1st quarter. BlueCrest Capital Management Ltd now owns 187,872 shares of the medical research company’s stock valued at $37,450,000 after buying an additional 121,602 shares during the last quarter. TimesSquare Capital Management LLC raised its stake in shares of Bio-Rad Laboratories by 17.2% during the 1st quarter. TimesSquare Capital Management LLC now owns 611,700 shares of the medical research company’s stock valued at $121,936,000 after buying an additional 89,800 shares during the last quarter. Point72 Asset Management L.P. raised its stake in shares of Bio-Rad Laboratories by 640.9% during the 1st quarter. Point72 Asset Management L.P. now owns 94,100 shares of the medical research company’s stock valued at $18,758,000 after buying an additional 81,400 shares during the last quarter. Finally, Assenagon Asset Management S.A. purchased a new position in shares of Bio-Rad Laboratories during the 2nd quarter valued at about $14,956,000. Institutional investors own 62.85% of the company’s stock.

Several equities analysts recently weighed in on the company. Zacks Investment Research lowered Bio-Rad Laboratories from a “hold” rating to a “sell” rating in a research note on Thursday, August 10th. TheStreet cut Bio-Rad Laboratories from a “b” rating to a “c+” rating in a report on Thursday, August 3rd. Jefferies Group LLC reiterated a “buy” rating and issued a $275.00 price objective on shares of Bio-Rad Laboratories in a report on Friday, July 14th. Wells Fargo & Company initiated coverage on Bio-Rad Laboratories in a report on Thursday, July 13th. They set an “outperform” rating and a $250.00 target price on the stock. Finally, Deutsche Bank AG upgraded Bio-Rad Laboratories from a “hold” rating to a “buy” rating and lowered their target price for the stock from $220.00 to $195.00 in a report on Wednesday, June 28th. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $228.80.

Bio-Rad Laboratories, Inc. (BIO) opened at 227.91 on Friday. The firm has a market cap of $6.75 billion, a P/E ratio of 450.42 and a beta of 0.93. Bio-Rad Laboratories, Inc. has a 52 week low of $154.89 and a 52 week high of $242.79. The company’s 50 day moving average is $221.09 and its 200-day moving average is $217.09.

In other news, EVP Michael Crowley sold 700 shares of the business’s stock in a transaction dated Friday, August 11th. The shares were sold at an average price of $215.91, for a total value of $151,137.00. Following the completion of the sale, the executive vice president now owns 2,060 shares of the company’s stock, valued at approximately $444,774.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 28.29% of the stock is currently owned by insiders.

TRADEMARK VIOLATION NOTICE: This report was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this report on another site, it was stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this report can be accessed at https://www.dailypolitical.com/2017/09/16/bio-rad-laboratories-inc-bio-shares-bought-by-schwab-charles-investment-management-inc.html.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.